Keywords: داروهای ضد انعقاد; Multiple myeloma; Second primary malignancies; Immunomodulatory drugs; Proteasome inhibitors; Plerixafor;
مقالات ISI داروهای ضد انعقاد (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: داروهای ضد انعقاد; VTE; venous thromboembolism; HSCT; hematopoietic stem cell transplant; LMWH; low molecular weight heparin; IMIDs; immunomodulatory drugs; AML; acute myeloid leukemia; IQR; interquartile range; TAT; thrombin antithrombin; FVII; factor VII; FVIII; factor VI
Keywords: داروهای ضد انعقاد; Bortezomib; Daratumumab; Dexamethasone; Epigenetic aberrations; Immunomodulatory drugs; Lenalidomide; Microenvironment; P-glycoprotein; Proteasome inhibitors;
Keywords: داروهای ضد انعقاد; Cardiac amyloidosis; Multiple myeloma; TTR; Cardiotoxicity; Proteasome inhibitors; Immunomodulatory drugs;
Keywords: داروهای ضد انعقاد; Multiple myeloma; Pharmacologically-dosed ascorbic acid; Apoptosis-inducing factor 1; MM; multiple myeloma; ROS; reactive oxygen species; SMM; smoldering MM; IMIDs; immunomodulatory drugs; ASCT; autologous stem cell transplantation; CRs; complete remissio
Keywords: داروهای ضد انعقاد; multiple myeloma; immunomodulatory drugs; proteasome inhibitors; treatment; side effects;
Keywords: داروهای ضد انعقاد; CVA; cerebrovascular accident; CT; computerized tomography angiography; DVT; deep venous thrombosis; ETP; endogenous thrombin potential; IMiD; immunomodulatory drugs; MM; multiple myeloma; TF; tissue factor; TG; thrombin generation; PE; pulmonary embolism
Keywords: داروهای ضد انعقاد; Myeloma; Maintenance; Autologous transplant; Immunomodulatory drugs;
Keywords: داروهای ضد انعقاد; Multiple myeloma; Translantation; Allogeneic; Bortezomib; Immunomodulatory drugs;
Keywords: داروهای ضد انعقاد; TME; tumor microenvironment; NHSC; non hematopoietic stromal cells; MSC; mesenchymal stem cells; MF; myofibroblasts; CAF; cancer associated fibroblasts PGE2 prostaglandin E2; VEC; vascular endothelial cells; LEC; lymphatic endothelial cells; PDGFR; platel
Keywords: داروهای ضد انعقاد; Immune surveillance; Tumor microenvironment; Immunomodulatory drugs; Immune checkpoint; Tumor-associated macrophages
Keywords: داروهای ضد انعقاد; CRBN expression; Immunomodulatory drugs; Multiple myeloma; Prognosis; Treatment;
Keywords: داروهای ضد انعقاد; Lenalidomide; Immunomodulatory drugs; Multiple myeloma; Myelodisplastic syndromes; Amyloidosis; Adverse cutaneous reactions; Stevens-Johnson syndrome; Erythema multiforme; Toxic epidermal necrolysis;
Keywords: داروهای ضد انعقاد; Herpes simplex virus encephalitis; Inflammation; Antiviral agents; Immunomodulatory drugs; Artesunate; Rapamycin
Keywords: داروهای ضد انعقاد; alergiczny nieżyt nosa; probiotyki; leki immunomodulujące; leki ziołowe; roztwory soliAllergic rhinitis; Probiotics; Immunomodulatory drugs; Herbal drugs; Saline solutions
Keywords: داروهای ضد انعقاد; Multiple myeloma; Relapsed/refractory; Complete remission; Prognostic factors; Immunomodulatory drugs; Proteasome inhibitors; Emerging agents;
Immunomodulatory drugs in AL amyloidosis
Keywords: داروهای ضد انعقاد; AL amyloidosis; Immunomodulatory drugs; Thalidomide; Lenalidomide; Pomalidomide;
Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment
Keywords: داروهای ضد انعقاد; Bendamustine; Bisphosphonates; Immunomodulatory drugs; Proteasome inhibitors; Stem cell transplantation;
Nawrotowa postaÄ szpiczaka plazmocytowego leczona dÅugotrwale lenalidomidem w monoterapii - opis przypadku
Keywords: داروهای ضد انعقاد; szpiczak plazmocytowy; leki immunomodulujÄ
ce; lenalidomid; Multiple myeloma; Immunomodulatory drugs; Lenalidomide;
The clinical significance of cereblon expression in multiple myeloma
Keywords: داروهای ضد انعقاد; Multiple myeloma; Cereblon; Gene expression profiling; Immunomodulatory drugs; Biological markers;
POMALIDOMID - nowy immunomodulujÄ
cy lek w terapii szpiczaka plazmocytowego
Keywords: داروهای ضد انعقاد; pomalidomid; leki immunomodulujÄ
ce; szpiczak plazmocytowy; Pomalidomide; Immunomodulatory drugs; Multiple myeloma;
Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
Keywords: داروهای ضد انعقاد; Multiple myeloma; Adoptive immunotherapy; NK cells; Chimeric antigen receptor; CD138 (syndecan-1); α-MEM; alpha modification of Eagle's minimum essential medium; ATCC; American type culture collection; CAR; chimeric antigen receptor; GvM; graft-vs-myelom
ReviewImmunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes
Keywords: داروهای ضد انعقاد; 5q- deletions; Hematologic malignancies; Immunomodulatory drugs; Lenalidomide; Myelodysplastic syndromes; Thalidomide;
Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Keywords: داروهای ضد انعقاد; Treatment late effects; Immunomodulatory drugs; Age
Leki immunomodulujÄ
ce - przeÅom w leczeniu nowotworów hematologicznych
Keywords: داروهای ضد انعقاد; leki immunomodulujÄ
ce; szpiczak plazmocytowy; zespoÅy mielodysplastyczne; chÅoniaki nieziarnicze; przewlekÅa biaÅaczka limfocytowa; Immunomodulatory drugs; Multiple myeloma; Myelodysplastic syndromes; Non-Hogdkins' lymphomas; Chronic lymphocytic le
Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia
Keywords: داروهای ضد انعقاد; Chronic lymphocytic leukemia; Immunodeficiency; T-cell function; Immunomodulatory drugs; Adoptive T-cell therapies;
Cataract surgery in patients with history of uveitis
Keywords: داروهای ضد انعقاد; Uveitis; Cataract; Immunomodulatory drugs; Intraocular lens biocompatibility
Mechanism of immunomodulatory drugs in multiple myeloma
Keywords: داروهای ضد انعقاد; Multiple myeloma; Treatment; Immunomodulatory drugs; Thalidomide; Lenalidomide; Pomalidomide;
Biomarkers and immune-modulating therapies for Type 2 diabetes
Keywords: داروهای ضد انعقاد; immunotherapy; type 2 diabetes; immunomodulatory drugs; obesity; biomarkers; autoimmunity; inflammation
Long-Term Persistence With the Immunomodulatory Drugs for Multiple Sclerosis: A Retrospective Database Study
Keywords: داروهای ضد انعقاد; immunomodulatory drugs; medication persistence; multiple sclerosis
Can we change the disease biology of multiple myeloma?
Keywords: داروهای ضد انعقاد; Multiple myeloma; Cell biology; Bone marrow microenvironment; Mode of action; Immunomodulatory drugs; Proteosome inhibitors
Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Concise Review
Keywords: داروهای ضد انعقاد; Allogeneic stem cell transplant; Donor lymphocyte infusion; Immunomodulatory drugs; Multiple myeloma; Reduced intensity transplantation
Myélome multiple : diagnostic clinique et perspective de traitement. Recommandations de l'International Myeloma Working Group (IMWG)
Keywords: داروهای ضد انعقاد; Multiple myeloma; Monoclonal gammopathy of undetermined significance; Immunomodulatory drugs; Myélome multiple; Gammapathie monoclonale de signification indéterminée (MGUS); Molécules immunomodulatrices;
Vaccines and Vaccine Adjuvants as Biological Response Modifiers
Keywords: داروهای ضد انعقاد; Immunomodulatory drugs; Cytokines; Vaccine adjuvants;
Actualités thérapeutiques de la sclérose en plaques
Keywords: داروهای ضد انعقاد; Sclérose en plaques; Immunomodulateur; interféronβ; Acétate de glatiramère; Mitoxantrone; Natalizumab; CyclophosphamideMultiple sclerosis; Immunomodulatory drugs; Interferon beta; Glatiramer acetate; Mitoxantrone; Natalizumab; Cyclophosphamide
Incorporating novel agents in the treatment of myelodysplastic syndromes
Keywords: داروهای ضد انعقاد; Myelodysplastic syndrome; Hypomethylating agents; Immunomodulatory drugs; Azacitidine; Decitabine; Lenalidomide; Histone deacetylase inhibitors; Farnesyl-transferase inhibitors;
CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet
Keywords: داروهای ضد انعقاد; T-bet, T-box protein; CTCL, cutaneous T cell lymphoma; IL-12Rβ2, IL-12 receptor beta chain 2; AHR, spontaneous airway hyper-responsivenessT lymphocytes; Immunomodulatory drugs; CC-4047; T-bet; GATA-3; Th1 and Th2 cells
Lenalidomide: A new therapy for multiple myeloma
Keywords: داروهای ضد انعقاد; Lenalidomide; Multiple myeloma; Dexamethasone; Immunomodulatory drugs
Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment
Keywords: داروهای ضد انعقاد; Multiple sclerosis; Relapses; Progression; Disability; Immunomodulatory drugs
Immunomodulatory compounds from Pestalotiopsis leucothës, an endophytic fungus from Tripterygium wilfordii
Keywords: داروهای ضد انعقاد; Cytokines; Cytotoxicity; Fungal compounds; Immune mediated diseases; Immunomodulation; Immunomodulatory drugs; Medicinal fungal compounds; Pestalotiopsis leucothës; Tripterygium wilfordii; Traditional Chinese medicine;